EARNIX
23.5.2024 21:16:26 CEST | Business Wire | Press release
Earnix, the leading global provider of AI-based SaaS solutions for financial services, today releases a high-level report highlighting the transformative potential of synthetic data to accelerate profitable growth and risk understanding in the context of the unique specialty London insurance market.
The white paper Reshaping London’s Specialty Market -The Impact of Technology and Data highlights the pivotal role that synthetic data - data that is produced, rather than gathered - will play in the future success of the market.
While synthetic data has been utilized in academia for decades, it's only recently gained traction in mainstream commercial applications. According to Gartner, synthetic data accounted for just 1% of data in 2021 but is projected to grow to 60% by 2024. Technological advancements like generational adversarial networks, transformers, and large language models have significantly increased the speed and volume of synthetic data created.
At the same time, the increasing demand for data in specialty insurance has prompted underwriters and brokers to begin harnessing synthetic data to supplement existing datasets, improving risk assessment efficiency. This is because synthetic data offers solutions to several key challenges in the London Market:
- Filling Data Gaps: Specialty insurers can harness synthetic data to access necessary data for product development and testing without compromising security or customer privacy. This has led to a surge in innovative ideas and technology deployment in insurance.
- Privacy and Security: Synthetic data maintains confidentiality while enabling critical analysis. In a world of widespread data availability, synthetic data techniques are essential to ensure customer data is not vulnerable to identity theft or fraud.
- Analytical Support: Synthetic data supports more accurate modeling, simulation, and testing, particularly in assessing extreme or rare events crucial for the specialty market, such as floods or hurricanes and fraud detection. Insurers can simulate these events to develop robust risk models without waiting for actual occurrences.
- Simulations, Stress Testing, and Data Expansion: Generating synthetic data improves the performance of predictive models, enhancing fraud detection and other analytical insights. It allows insurers to simulate and stress-test models in new situations, enabling them to introduce new products or expand into new segments or territories with limited existing data.
Earnix CEO Robin Gilthorpe said:
“The digital transformation of the London market’s complex specialty lines of business has only just begun. While it is a market-wide and fundamental shift in the way specialty insurers and reinsurers do business, it is not a one-size-fits-all solution. However, synthetic data coupled with AI, machine learning, and advanced analytics, holds promise for addressing various challenges in specialty insurance, including data gaps, privacy and security concerns, and fraud detection, among others.
Data plays a crucial role in revenue, profitability, and market share- particularly in this complex market where insight at a granular level can make a significant difference at a macro level. Specialty brokers and insurers know that in this rapidly evolving market, the ability to grow through change is paramount. Our white paper underscores the pivotal role of synthetic data in reshaping the London Market and outlines the next steps available to specialty insurers to harness the unparalleled opportunities for informed decision-making and enhanced operational efficiency.”
Download the report here.
For more information about Earnix, please visit www.earnix.com.
About Earnix
Earnix is the premier provider of mission-critical, cloud-based intelligent solutions across pricing, underwriting, rating, and product personalization. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. Earnix has been innovating for insurers and banks since 2001, with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel. For more information please visit: earnix.com.
Contact Earnix via LinkedIn, X, and Facebook. Read the Earnix blog.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523060502/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
